Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647633 · ClinicalTrials.gov registry record · Phase 1
Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash
A Phase 1 study of Allergic Rhinitis, sponsored by Drexel University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01647633: Completed Phase 1 study of Allergic Rhinitis, sponsored by Drexel University.
NCT01647633 is a Phase 1 study of Allergic Rhinitis that has completed, run by Drexel University. The registered enrollment target is 17 participants, below the 105-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01647633, a Phase 1 study of Allergic Rhinitis, has completed, sponsored by Drexel University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
Over 20 million Americans have allergic nasal symptoms including stuffiness, sneezing and a "runny" nose. AkPharma's Calcium Glycerophosphate used as a nasal spray wash is believed to improve these symptoms without side effects common to over the counter and prescription medication. It is hypothesized that Calcium Glycerophosphate will have a perceived improvement in breathing comfort.
Primary Outcome
Perceived improved comfort breathing is anticipated as primary outcome
Conditions Studied
Interventions
- OTHER Calcium Glycerophosphate Nasal Spray Wash
Study Locations (1)
Pennsylvania
- Drexel University College of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT01647633 record still lists
NCT01647633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 105-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which Calcium Glycerophosphate Nasal Spray Wash is the first listed.
NCT01647633 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01647633 about?
NCT01647633 is a clinical study titled "Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash". Over 20 million Americans have allergic nasal symptoms including stuffiness, sneezing and a "runny" nose. AkPharma's Calcium Glycerophosphate used as a nasal spray wash is believed to improve these symptoms without side effects common to over the counter and prescription medication. It is hypothesiz...
What is the current status of trial NCT01647633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2012-05. Estimated completion is 2015-05.
What conditions does trial NCT01647633 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT01647633?
The interventions under investigation include: Calcium Glycerophosphate Nasal Spray Wash (OTHER).
Who is sponsoring clinical trial NCT01647633?
This trial is sponsored by Drexel University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01647633 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01647633's enrollment target sits among peer trials
17 23rd of 23 higher than 1 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device
COMPLETED · Phase 1
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia